RecruitingPHASE1, PHASE2NCT06609889
A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
Studying Lafora disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Berge Minassian
- Principal Investigator
- Berge Minassian, MDUniversity of Texas Southwestern Medical Center
- Intervention
- ION283(genetic)
- Enrollment
- 10 enrolled
- Eligibility
- 10-18 years · All sexes
- Timeline
- 2024 – 2028
Study locations (1)
- Childrens Health, Dallas, Texas, United States
Collaborators
Elpida Therapeutics SPC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06609889 on ClinicalTrials.gov